This round of financing will support Alebund in advancing the development and commercial activities of its pipelines in renal disease and to accelerate the development of multiple clinical-stage ...

OLC is being developed as a more patient-friendly alternative to Takeda's phosphate binder Fosrenol (lanthanum carbonate), which is sold in a large chewable tablet formulation, while other drugs ...

Cinacalcet does not pharmacokinetically interfere with the calcium-phosphate binder, sevelamer, inhibitors of the gastric proton pump or warfarin derivatives. Concomitant food intake (compared ...

Phosphate binders are integral to hyperphosphatemia management in patients with end-stage kidney disease. This objective of the Unicycive study was to demonstrate the pharmacodynamic equivalence ...

Detailed price information for Unicycive Therapeutics Inc (UNCY-Q) from The Globe and Mail including charting and trades.